1. Fujiwara N, Matsushita Y, Tempaku M, Tachi Y, Kimura G, Izuoka K, Hayata Y, Kawamura S, Eguchi A, Nakatsuka T, Sato M, Ono A, Murakami E, Tsuge M, Oka S, Hayashi A, Hirokawa Y, Watanabe M, Parikh N, Singal AG, Marrero JA, Hoshida Y, Mizuno S, Tateishi R, Koike K, Fujishiro M, Nakagawa H. AI-based phenotyping of hepatic fiber morphology to inform molecular alterations in metabolic dysfunction-associated steatotic liver disease. Hepatology. In press.
2. Nakagawa H. Lipogenesis and MASLD: re-thinking the role of SREBPs. Arch Toxicol. In press.
3. Iwasa M, Sugimoto R, Eguchi A, Tamai Y, Shigefuku R, Fujiwara N, Tanaka H, Kobayashi Y, Ikoma J, Kaito M, Nakagawa H. Effectiveness of 1-year pemafibrate treatment on steatotic liver disease: the influence of alcohol consumption. Eur J Gastroenterol Hepatol. 2024 Jun 1;36(6):793-801.
4. Shigefuku R, Iwasa M, Tanaka H, Tsukimoto M, Tamai Y, Fujiwara N, Yoshikawa K, Tameda M, Ogura S, Nakagawa H. Prognostic Significance of Psoas Muscle Index in Unresectable Hepatocellular Carcinoma: Comparative Analysis of Lenvatinib and Atezolizumab Plus Bevacizumab. J Clin Med. 2024 Oct 4;13(19):5925.
5. Fujiwara N, Kimura G, Nakagawa H. Emerging Roles of Spatial Transcriptomics in Liver Research. Semin Liver Dis. 2024 May;44(2):115-132.
6. Nakagawa H. New ubiquitomic subtypes in hepatocellular carcinoma: Insights for future therapeutic approaches. Hepatology. In press.
7. Fujiwara A, Takemura K, Tanaka A, Matsumoto M, Katsuyama M, Okanoue T, Yamaguchi K, Itoh Y, Iwata K, Amagase K, Umemura A.Carfilzomib shows therapeutic potential for reduction of liver fibrosis by targeting hepatic stellate cell activation. Sci Rep 2024 Aug 20;14(1):19288.